Royalty Pharma has sold it's $485 million interest in Ibrutinib to Aisling Capital and Clarus Ventures in a royalty financing round.
Royalty Pharma announced that, pursuant to a collaboration with Aisling Capital and Clarus Ventures, it has sold to Aisling and Clarus approximately 20% of the royalty financing interest in Ibrutinib it recently acquired from Quest Diagnostics for a pro rata percentage of the $485 million Royalty Pharma paid to Quest for the royalty.
Pharmacyclics and Janssen Pharmaceutical's Ibrutinib was filed with the U.S. Food and Drug Administration in July 2013 for relapsed/refractory mantle cell lymphoma and relapsed/refractory chronic lymphocytic leukemia after receiving Breakthrough Therapy Designation from FDA earlier this year, prior to this royalty financing deal.
Ibrutinib has received three of the eight Breakthrough Therapy Designations granted by the FDA to date in oncology, prior to the royalty financing round.
Royalty Pharma is the industry leader in acquiring royalty financing interests in marketed and late stage biopharmaceutical products.
Clarus Ventures is a life sciences venture capital firm founded by a team of accomplished investment and operating professionals.
Aisling Capital is a life sciences-dedicated venture capital firm with over US$1.6 billion under management.
Report: Lymphoma Partnering
Report: Leukemia Partnering
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity